ISPOR Forums
Monday, 31 October 2016
17:00 - 18:00
BREAKOUT SESSION

17:00 - 18:00
Room: Hall F2 (L0)
F1: EXTENDING COST-EFFECTIVENESS ANALYSIS, PARTIAL OPTIMIZATION MODELLING, AND FISCAL MODELLING IN VACCINE VALUE ASSESSMENTS
Moderator:

Hans Severens, PhD, Professor, Evaluation in Health Care, iBMG - Institute of Health Policy & Management and iMTA - Institute of Medical Technology Assessment, Erasmus University, Rotterdam, The Netherlands

Speakers:

Baudouin Standaert, MD, PhD, Director, Health Economics, GSK Vaccines, Wavre, Belgium

Mark Connolly, PhD, Guest Researcher, University of Groningen, the Netherlands and Managing Director, Global Market Access Solutions LLC, Geneva, Switzerland

Raymond Hutubessy, PhD, MSc, Senior Health Economist, Initiative for Vaccine Research, World Health Organization (WHO), Geneva, Switzerland

DESCRIPTION:

DESCRIPTION:  The decision to introduce a new vaccination program in a country is a process in which multiple decision makers participate. Each decision maker considers the value of the new vaccination program from different perspectives and is, therefore, interested in different measures of economic value. These measures include value for money and net present value and can be considered to be part of a complete assessment of economic value. The ISPOR Task Force on the Economic Evaluation of Vaccines for Infectious Diseases has selected three methods currently being used to assess the value of new vaccination programs (cost-effectiveness analysis, partial optimization modelling, and fiscal modelling). At this Forum, we will present an initial set of guidelines (perspective, comparator, time horizon, discounting, model structure, data requirement, outcome measures, uncertainty evaluation, transparency, and validation) for each of these methods as well as an exploration of how they can be extended beyond a focus on individual health outcomes to include a broader set of outcomes for the individual, household and the community. We will ask Forum participants to give the Task Force feedback on the initial guidelines for the traditional and extended value assessments.
Presented by the ISPOR Economic Evaluation of Vaccines Designed to Prevent Infectious Disease: Good Practices Task Force

18:15 - 19:15
BREAKOUT SESSION

18:15 - 19:15
Room: Hall D (L -2)
F2: PATIENT ENGAGEMENT: STOPPING TO DEFINE IT
Moderator:

Todd Berner, MD, Head Global Medical Affairs Strategy, Immunology, Baxalta, Bannockburn, IL, USA

Speakers:

Eleanor M. Perfetto, PhD, RPh, MS, Senior Vice President, Strategic Initiatives, National Health Council, Washington, DC, USA and Professor, Pharmaceutical Health Services Research, School of Pharmacy, University of Maryland, Baltimore, MD, USA

Maya L. Hanna, MPH, Doctoral Student, School of Pharmacy, University of Maryland, Baltimore, MD, USA

Rob Camp, BS, Communications Manager, European Patients' Academy (EUPATI), Barcelona, Spain

Russell Wheeler, Patient Advocate, Leber Hereditary Optic Neuropathy, Winchester, UK

DESCRIPTION:

DESCRIPTION:  Recently, the terms “patient engagement” and “patient-centered” have been used extensively, but rarely defined or commonly understood in the context of health care and research. To involve patients in research and health care delivery with the goal of improving health outcomes important to them, users need to understand the full scope of patient engagement and to define the attributes of these terms. The Patient Engagement in Research Working Group conducted a systematic review to identify existing definitions used over the past 10 years for patient engagement and centeredness, and 14 other patient-related terms in the context of health care research and practice. The Working Group screened 1371 abstracts and reviewed full-text articles seeking definitions. This forum will allow the Working Group to present the results from the systematic review and the resulting analyses used to identify emergent themes. Preliminary results of definitions for patient-related terms in the scope of health economics and outcomes research will be presented for audience discussion.
Presented by the ISPOR Patient Centered Special Interest Group


18:15 - 19:15
Room: Hall A (L2)
F3: GENERATING EVIDENCE OF THE ADDED VALUE OF ‘PRECISION’ MEDICINE
Moderator:

Katherine Payne, PhD, MSc, DipClinPharm, BPharm, MRPharmS, Professor of Health Economics, The University of Manchester, Manchester, UK

Speakers:

Eric Faulkner, MPH, Vice President, Precision and Transformative Technology Solutions, Value Demonstration, Access and Commercial, Evidera, and Assistant Professor, Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina at Chapel Hill, Chapel Hill, SC, USA

Uwe Siebert, MD, MPH, MSc, ScD, Professor & Chair, Department of Public Health and Health Technology Assessment, UMIT - University for Health Sciences, Medical Informatics and Technology, Austria, Adjunct Professor, Health Policy and Management, Harvard School of Public Health, Boston, MA, USA, and Director, Division for HTA, ONCOTYROL – Center for Personalized Cancer Medicine, Hall i.T., Austria

Anke-Peggy Holtorf, PhD, MBA, Managing Director, Health Outcomes Strategies, GmbH, Basel, Switzerland

Gurmit Sandhu, B Pharm (Hons), MBA, MPH, Patient Engagement Specialist, Gurmit Sandhu Consulting GmbH, Basel, Switzerland

DESCRIPTION:

DESCRIPTION: Different terms have emerged into practice, such as precision, personalized, stratified, individualized medicine, all generally used to refer to the use of technology to more effectively target health care interventions to sub-groups of people that are more likely to accrue more benefits than harm. Given the potential for increasing numbers of new technologies and interventions that promise to deliver precision medicine and that will impact health care budgets, it is vital to generate evidence of their added value. A number of challenges have been identified, but to date, there have been few evidence-based suggestions on how to meet these challenges. The aim of this interactive session will be to understand the audiences view on what precision medicine is and present some potential solutions to key types of challenges under the headings: methodological, technical, practical and organizational, and the patient perspective.

The session will start with the moderators asking the audience to indicate their view on suggested definitions of personalized, stratified, individualized and precision medicine. Anke-Peggy Holtorf will start the presentations by describing some examples of methodological challenges and suggest a research agenda to address these. Uwe Siebert will describe the technical challenges involved when developing decision-analytic models for benefit-harm analysis and economic evaluation. Recent examples from the area of oncology will be presented to show some potential solutions. Eric Faulkner will describe the practical and organizational challenges from the perspective of industry and health care systems that need to be solved to generate a sufficient and timely evidence base, such as the need to address budget silos and developing timely and effective services. Eric will also show how different approaches, such as headroom analysis or the use of observational data can be used to solve practical challenges. Gurmit Sandhu will focus on why it is important to take into account the patient’s perspective when introducing precision medicine into clinical practice. The session will conclude with an interactive session, in which the audience is invited to contribute to developing a future research agenda to generate an evidence base to understand the added value of precision medicine.

Presented by the ISPOR Personalized / Precision Medicine Special Interest Group


18:15 - 19:15
Room: Hall F2 (L0)
F4: BURDEN OF HEPATITIS C IN CENTRAL AND EASTERN EUROPEAN COUNTRIES
Moderator:

Zoltán Kaló, PhD, Professor of Health Economics, Eötvös Loránd University (ELTE), Budapest, Hungary

Speakers:

Guenka Petrova, DSci, Professor, Social Pharmacy, Medical University Sofia, Faculty of Pharmacy, and President, ISPOR Bulgaria Chapter, Sofia, Bulgaria

Lubov Krasnova, MD, PhD, Senior Researcher, Department of Hematology & Geriatrics, First Sechenov State Medical University, Moscow, Russian Federation

Anush Perikhanyan, MPH, Researcher, Pharmaceutical Management, Yerevan State Medical University, and President, ISPOR Armenia Chapter, Yerevan, Armenia

Elena Pyadushkina, PharmD, Researcher, Russian Presidential Academy of National Economy and Public Administration, Moscow, Russian Federation

DESCRIPTION:

DESCRIPTION: The medical and economic burden of hepatitis C is more significant in lower income countries than in high income economies in Europe. This Forum will focus on introducing highly effective new medicines in this field, discussing better understanding of disease burden, and trade-offs between health, affordability and equity objectives. Speakers will aim to review existing information on the burden of hepatitis C in Central and Eastern European (CEE) countries and identify evidence gaps to facilitate informed policy decisions about new medicines.
Presented by the ISPOR CEE Network


18:15 - 19:15
Room: Hall F1 (L0)
F5: DRUG PRICING IN ADRIATIC COUNTRIES – IS REFERENCE PRICING THE BEST OPTION?
Moderator:

Tarik Catic, PhD(s), Past President, ISPOR Bosnia and Herzegovina Chapter, Sarajevo, Bosnia

Speakers:

Rok Hren, PhD, MSc IHP (HE), Professor, University of Ljubljana, Ljubljana, Slovenia

Ljubica Suturkova, PhD, President, ISPOR Republic of Macedonia Chapter, and Professor, Faculty of Pharmacy, UKIM-Skopje, Skopje, Macedonia

Pero Draganić, PhD, MD, President, ISPOR Croatia Chapter, and Assistant Professor, HALMED, Zagreb, Croatia

Dragana Atanasijevic, MD, MSc, President, ISPOR Serbia Chapter, and Consultant, HTA & Healthcare Quality Improvement, Belgrade, Serbia

DESCRIPTION:

DESCRIPTION:

Drug pricing rules and trends will be presented from the perspective of countries in the Adriatic region. Speakers will discuss each country’s experience and the impact of prices on access to medicines, its quality and pharmaceutical expenditure. Since most of the countries in the region share similar health care organization and financing system, it will be an opportunity to discuss trends and propose which model is the most suitable for these countries in order to effectively distribute pharmaceutical budgets and ensure access to medicines.

Presented by the ISPOR CEE Network


18:15 - 19:15
Room: Hall E1 (L0)
F6: THE ECONOMIC BURDEN OF COUNTERFEIT MEDICINES IN AFRICA: SITUATION ANALYSIS AND PROPOSED SOLUTIONS
Moderator:

Mahmoud Diaa Elmahdawy, PharmD, President, ISPOR Egypt Chapter, Director, AMAC Market Access, Novartis, Health Economics, and Lecturer of Clinical and Hospital Pharmacy, Misr International University, Cairo, Egypt

Speakers:

Kasem Akhras, PharmD, Head, Market Access, Middle East and North Africa (MENA), Novartis Pharma Services AG, Dubai, United Arab Emirates

Ilse Truter, DCom, BPharm, MSc, PhD, MPS, Professor in Pharmacy & Leader, Drug Utilization Research Unit (DURU), Department of Pharmacy, School of Medicinal Sciences, Faculty of Health Sciences, Nelson Mandela Metropolitan University, Port Elizabeth, South Africa

DESCRIPTION:

DESCRIPTION:

Trade of counterfeit and substandard medicines is a multi-billion dollar business worldwide. Their impact in Africa, where only very limited resources for laboratory identification of these medications exist, have not been quantified in terms of clinical, humanistic and economic outcomes. In this Forum, speakers from Africa will discuss the current real-life situations of counterfeit medicines in their countries with emphasis on the economic burden and solutions that are being explored in addressing the problem and reducing the number of counterfeit and substandard medicines on the African market.

Presented by the ISPOR Africa Network


18:15 - 19:15
Room: Hall E2 (L0)
F7: A STRUCTURED DEBATE REGARDING THE NATIONAL HEALTH ECONOMICS GUIDELINES IN SOUTHERN EUROPE
Moderator:

Carlos Gouveia Pinto, PhD, Associate Professor, ISEG, Lisbon School of Economics and Management and President, ISPOR Portugal Chapter, Lisbon, Portugal

Speakers:

Jaime Espín, PhD, Professor, Andalusian School of Public Health, Granada, Spain

Luis Silva Miguel, MSc, PhD, Researcher, Research Centre on the Portuguese Economy, CISEP, Lisbon School of Economics & Management, University of Lisbon, Lisbon, Portugal

Lorenzo G. Mantovani, DSc, Associate Professor of Public Health, Research Centre on Public Health, University of Milano-Bicocca, Monza, Italy

Francesco Saverio Mennini, PhD, Professor, Faculty of Economics, Centre for Economic Evaluation and HTA (EEHTA), CEIS, University of Rome Tor Vergata, Rome, Italy

DESCRIPTION:

DESCRIPTION:  The ISPOR tool – Pharmacoeconomic Guidelines Around the World - features a listing and description of international official guidance regularly shaping formulary decisions. The periodic review of guidelines raises a few questions, such as-- What are the methodological challenges and political contestation involved in the establishment, review and use of the guidance. This forum will therefore explore the latest controversies regarding national health economic evaluation guidelines in the context of southern European regions via a moderated debate among experts. In doing so, this session seeks to provide analytical insight for analyzing and revisiting the national guidelines presented.
Presented by the ISPOR Portugal Chapter, ISPOR Spain Chapter, ISPOR Italy-Milan Chapter, and ISPOR Italy-Rome Chapter

Tuesday, 1 November 2016
17:45 - 18:45
BREAKOUT SESSION

17:45 - 18:45
Room: Hall E1 (L0)
F8: NEW ISSUES & EMERGING TRENDS IN HEOR: REVISING THE ISPOR CODE OF ETHICS
Moderator:

Richard J. Willke, PhD, Chief Science Officer, International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Lawrenceville, NJ, USA bio

Speakers:

Jessica Santos, PhD, Global Compliance and Quality Director, Kantar Health, Epsom, UK

Michael Drummond, MCom, DPhil, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK bio

Louise Parmenter, PhD, Vice President, Epidemiology & Outcomes Research, Real-World & Late Phase Research, Quintiles, Inc., Reading, UK

Gurmit Sandhu, B Pharm (Hons), MBA, MPH, Patient Engagement Specialist, Gurmit Sandhu Consulting GmbH, Basel, Switzerland

DESCRIPTION:

DESCRIPTION: The explosion of big data, the rise of health IT, genomic information, and social media, as well as the increased focus on patient centricity, privacy issues, and reproducibility of research results, has rendered the current ISPOR Code of Ethics outdated. In addition to the changes in the market, ISPOR has grown tremendously in membership and geographic reach since its 2008 publication. ISPOR’s influence on global health policy is likely to increase in the coming years. This potential could be undermined by perceptions of bias or other ethical issues surrounding the conduct of HEOR. Speakers will discuss the additions to the Code, the publications section, and the increased role of patients and other stakeholders on ISPOR’s Code of Ethics. Comments and feedback from the audience are appreciated!
Presented by the ISPOR Code of Ethics Task Force


17:45 - 18:45
Room: Hall F1 (L0)
F9: USES, APPLICATIONS, AND FUTURE DIRECTIONS OF THE ISPOR DIGEST OF INTERNATIONAL DATABASES
Moderator:

Carl Asche, PhD, MSc, Director, University of Illinois College of Medicine, Center for Outcomes Research, Peoria, IL, USA

Speakers:

Elisabeth M. Oehrlein, BA, PhD Candidate, Pharmaceutical Health Services Research, University of Maryland, School of Pharmacy, Baltimore, MD, USA

Brian Seal, RPh, MBA, PhD, Director, Global Outcomes Research, Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA

DESCRIPTION:

DESCRIPTION:  The Digest of International Databases, originally developed by ISPOR in 2008, provides a summary of key attributes of health care databases around the world. In order for the Digest to remain a useful resource to researchers, the information provided must be accurate, up-to-date, and comprehensive. The ISPOR Special Interest Group (SIG) on Digest of Databases is working to improve the format, search, and print functions, while also working to ensure that information is up-to-date and the list of Databases is comprehensive. The SIG is also working to provide student-specific information, such as discounted costs. The audience will be invited to comment and provide feedback on future directions and our progress to date, which includes revised Digest Domains, an updated list of Databases, incorporation of peer review, and revised processes for keeping the information current.
Presented by the ISPOR Digest of International Databases Special Interest Group


17:45 - 18:45
Room: Hall A (L2)
F10: HEALTH ECONOMIC MODELING IN ONCOLOGY
Moderator:

Noemi Muszbek, MSc, Senior Research Scientist, Evidera, London, UK

Speakers:

Sorrel Wolowacz, PhD, Senior Director, Market Access and Outcomes Strategy, RTI Health Solutions, Manchester, UK

Agnes Benedict, MSc, Executive Director, Evidera, Budapest, Hungary

DESCRIPTION:

DESCRIPTION:  The increasing attention on assessing the value of oncology products has resulted in close scrutiny of the validity of health economic models evaluating the cost-effectiveness of new interventions. The field of oncology outcomes research is complicated by the diversity of diseases within oncology, the rapidly changing nature of treatments, and the complexities of measuring cost and quality of life/patient reported outcomes. The Oncology Health Economic Modeling Working Group structured a systematic literature review to focus on contemporary and existing health economic modeling methods in advanced oncology and the availability of data on health utility, disease management, treatment patterns, resource use and costs in the post-progression/post-response period. This forum will present the literature review, the search criteria and challenges from the point of view of multiple stakeholders. The audience will be invited to comment and provide feedback on the project. The presentation may be of interest to health economists, modelers, outcomes researchers and anyone involved in health technology assessment of oncology therapies.
Presented by the ISPOR Oncology Health Economic Modeling – Post-Progression Working Group


17:45 - 18:45
Room: Hall E2 (L0)
F11: RESULTS FROM MCDA PAYER CRITERIA: WEIGHTS & PREFERENCES IN THE CEE REGION
Moderator:

Vladimir Zah, PhD Candidate and Chair, ISPOR CEE Network Executive Committee, Health Economist, Belgrade, Serbia

Speakers:

Oresta Piniazhko, PhD, PhD Candidate & Assistant Professor, Department of Management and Economy of Pharmacy, Medicine Technology and Pharmacoeconomics, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine

Tomas Dolezal, MD, PhD, Scientific Director, Institute of Health Economics and Technology Assessment, iHETA, Prague, Czech Republic

Ioannis Yfantopoulos, PhD, President, ISPOR Greece Chapter, and Professor of Health Economics, Economics and Political Science, University of Athens, Athens, Greece

Aleksandra Zawodnik, MSc Pharm, PhD Candidate, Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland

DESCRIPTION:

DESCRIPTION: In this Forum panelists will present and discuss findings of the collected MCDA (Multi-Criteria Decision Analysis) payer preferences across different Central and Easter Europe (CEE) countries, relating to oncology, rare diseases and medical devices. Comparison will be made between different countries criteria prioritization. Furthermore, speakers will explain national payer's MCDA perspective and the impact of different criteria as a potential CEE “core” MCDA model, with demonstration of intra-CEE countries transferability.
Presented by the ISPOR CEE Network


17:45 - 18:45
Room: Hall D (L -2)
F12: THE VALUE OF MULTI-STAKEHOLDER PARTNERSHIP IN ADVANCING PATIENT ACCESS IN CENTRAL AND EASTERN EUROPE
Moderator:

Dominik Tomek, PharmD, MPH, PhD, President, ISPOR Slovakia Chapter, and Senior Researcher, Faculty of Medicine, Slovak Medical University, Bratislava, Slovak Republic

Speakers:

Nicola Bedlington, Secretary General, European Patients’ Forum and Co-Founder, The Patient Access Partnership PACT, Brussels, Belgium

Stanimir Hasurdjiev, MD, Secretary-General, Patient Access Partnership, Brussels, Belgium

Tamas Agh, MD, PhD, Principal Researcher, Syreon Research Institute, Budapest, Hungary

Martin Višňanský, PharmDr., MBA, PhD, MSc, Lecturer, University of Veterinary Medicine and Pharmacy, Kosice, Slovakia

DESCRIPTION:

DESCRIPTION: Over the last three decades Central and Eastern European (CEE) countries made great improvements in modernizing their health care systems and policies by rapidly adopting new methods, medications and innovative health technologies. However, despite these improvements, many still face significant challenges in the functioning and organization of their health systems: lack of resources, health technology assessment (HTA) implementation, lack of personnel, etc. One of the main challenges is the patient access to basic health care. This forum will highlight patients and experts views on advancing access to health care in the CEE region.
Presented by the ISPOR CEE Network


17:45 - 18:45
Room: Hall F2 (L0)
F13: THE SPANISH EXPERIENCE IN HEPATITIS C: FRIENDS OR FOES?
Moderator:

Carme Pinyol, MD, PhD, MSc, Director INNOVA STRATEGIC CONSULTING, President ISPOR Regional Spain Chapter, Barcelona, Spain

Speakers:

Pedro Gómez-Pajuelo, Health Economist, Ministry of Health, Madrid, Spain

Álvaro Hidalgo, PhD, Professor, Universidad de Castilla la Mancha, Toledo, Spain

Toni Gilabert, PhD, General Director of Medicines, Catalan Health Services, Barcelona, Spain

Iñaki Betolaza, Director of Pharmacy, Health Department of Basque Government, Vitoria-Gasteiz, Spain

DESCRIPTION:

DESCRIPTION: Last year, the Spanish Ministry of Health launched the Strategic Plan for Hepatitis C to ensure access to new treatments to all patients who need them. In the beginning, the estimated number of people affected by Hepatitis C was determined: 95,524 diagnosed, of which 51,964 were patients with fibrosis in F2, F3 and F4 grade, which are those who have been given priority when receiving treatment. At this moment, 52.000 patients have been treated with these drugs. Spain is the country which has more patients treated in Europe.

Regarding Price and reimbursement of these drugs, the Ministry of Health and the Ministry of Finance established with regional government a specific plan of financing for ensuring that prioritized VHC patients receive new antivirals. Negotiation with pharmaceutical companies included different mechanism of financing these drugs, CAP, price for treatment and price-volume agreement.

In this round table, we want to analyze the Spanish Plan and its deficiencies, different formulas used for negotiation at national and regional level and the real data obtained in registries of patients. We want also to think in the future: how to deal with new treatment and how to plan the elimination of Hepatitis C.

Presented by The ISPOR Spain Chapter

Contact ISPOR @ info@ispor.org | View Legal Disclaimer
© 2018 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.